Epilepsy in Alternating Hemiplegia of Childhood: Characteristics, Neuroimaging, and Response to Therapy (P4.6-069)
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: Describe the manifestations of epilepsy in Alternating Hemiplegia of Childhood (AHC) and our experience in managing it.
Background: AHC is characterized by recurrent episodes of hemiplegia, double hemiplegia, dystonia, and, frequently, epilepsy. However, the characteristics of epilepsy in AHC have yet to be described in detail.
Design/Methods: We analyzed clinical and electrophysiological data of a cohort of 50 consecutive AHC patients who underwent systematic evaluations as per our clinical pathway.
Results: 31/50 had epilepsy (seizure age of onset: 1.89±3.04 years). In seven, seizures preceded other AHC spells. Eighteen (58%) were drug resistant. Seventeen had focal seizures, frontal more frequently than temporal, then parietal, and occipital. Eleven had primary generalized seizures: 11 generalized tonic-clonic (GTC), 3 myoclonic, and 2 absence. Three had GTCs of unknown onset. Therapies included antiepileptics (31/31), ketogenic diet (6/31), repurposed drugs (11/31) and pulse steroids (2/31), and had mixed results. Vagal nerve stimulation resulted in >50% reduction in seizure frequency in 5/6. Although the majority had epileptiform EEGs, 7 initially had normal EEGs that later became epileptiform. MRI, normal in the majority, showed in some cerebral atrophy (3/31), cerebellar atrophy (3/31) or abnormal spectroscopy (4/5, all had prior status epilepticus-SE). Eleven (35%) had SE, refractory or super refractory in all. 8/11 had multiple SE episodes. 3/11 had regression after SE.26/50 also had, previously not characterized, spells we termed Reduced Awareness Spells (RAS), consisting of isolated lethargy, drowsiness, staring, and reduced responsiveness without concomitant clinical epileptic manifestations or EEG changes.
Conclusions: Epilepsy in AHC: 1) is focal or generalized, 2) can be the initial manifestation of AHC, 3) manifests high frequency of drug resistance and of often recurrent refractory SE that at times is followed by regression, and 4) RAS, likely non-epileptic in nature, occur frequently.
Disclosure: Dr. Uchitel has nothing to disclose. Dr. Helseth has nothing to disclose. Dr. Prange has nothing to disclose. Dr. McLean has nothing to disclose. Dr. Ghusayni has nothing to disclose. Dr. Sachdev has nothing to disclose. Dr. Hunanyan has nothing to disclose. Dr. Mikati has nothing to disclose.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.